Percutaneous Gelled Alcohol Sclerotherapy for Aggressive Angiomas: Evaluation of Feasibility, Safety, and Efficacy

Recruiting now

Conditions studied: Bone Angioma

In brief

The investigators aimed to evaluate efficacy and safety of a non-surgical protocol treatment combining transarterial embolization and percutaneous radiopaque gelled ethanol (RGE) sclerotherapy in a first procedure, then followed by vertebroplasty in a second procedure, to treat aggressive vertebral hemangioma patients in tertiary hospital. Exclusion criteria were age \<18-years old and any association with neurological deficit.

Key facts

Study ID

NCT06607731

Run by

Centre Hospitalier Universitaire de Saint Etienne

People needed

11

Starts

2024-06-25

Expected to finish

2024-12-01

Last updated by the study team

2024-10-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Every patients treated by gelled alcohol sclerotherapy for aggressive angiomas, in the University Hospital of Saint-Etienne.

You may not qualify if…

• Patients no treated by gelled alcohol sclerotherapy.

Where it is running

• CHU de Saint-Etienne — Saint-Priest-en-Jarez, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.